Program
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1
In Sichuan Biokin Pharmaceutical’s pipeline, Claudin18.2 ADC
. Its studies are mostly in Stomach Neoplasms · Adenocarcinoma Of Esophagus, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biokin (Shanghai) Biopharmaceuticalits history only | 22 open or running | phase 3since Apr 2, 2026 | Apr 1, 2024 | Jun 2027phase 1 · NCT06349811 |
| Sichuan Biokin Pharmaceuticalits history only | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | Feb 28, 2027phase 1 · NCT07021066 |
- Named in Sichuan Biokin Pharmaceutical’s own pipeline as
BL-M05D1 (Claudin18.2 ADC)
, phase 1, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 1, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsNew to Biokin (Shanghai) BiopharmaceuticalBiokin (Shanghai) Biopharmaceutical · NCT06349811 · 30 planned · China
- May 23, 2025Sichuan Biokin Pharmaceutical’s first study: phase 1 study in Adenocarcinoma Of EsophagusNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07021066 · 160 enrolled · United States
- Apr 2, 2026Phase 3 study in Stomach NeoplasmsPhase 3 reachedBiokin (Shanghai) Biopharmaceutical · NCT07518147 · 438 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Adenocarcinoma Of EsophagusSichuan Biokin Pharmaceutical · NCT07021066
- Jun 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsBiokin (Shanghai) Biopharmaceutical · NCT06349811
- Dec 2029Primary completion: phase 3 study in Stomach NeoplasmsBiokin (Shanghai) Biopharmaceutical · NCT07518147
TargetBeta
“Claudin18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a wild-type Fc-containing immunoglobulin (IgG) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) (5103F3) ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07518147Stomach Neoplasms · China | 3 | Recruiting | Biokin (Shanghai) Biopharmaceutical | Dec 2029 | 438 |
| NCT07021066Adenocarcinoma Of Esophagus · United States | 1 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Feb 28, 2027 | 160 |
| NCT06349811Locally Advanced or Metastatic Solid Tumors · China | 1 | Recruiting | Biokin (Shanghai) Biopharmaceutical | Jun 2027 | 30 |
How it is read
Names in the registry
- “BL-M05D1”, 3 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
- Adenocarcinoma Of Esophagus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.